Please login to the form below
personalised medicines
This page shows the latest personalised medicines news and features for those working in and with pharma, biotech and healthcare.
MHRA outlines two-year delivery plan with ‘patient first’ focus
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has revealed its new delivery plan, outlining its two-year strategy after departing from the European regulatory system. ... The MHRA plans to do this by evolving its regulatory
Latest news
-
Immuno-oncology, personalised medicine continues to drive pharma sector
Coming in after I-O and personalised medicines as the top most impactful trends was the growing role of real-world evidence and a rise in the use of electronic health ... Personalised medicines have been identified as key treatments by the UK’s
-
Incyte signs lymphoma deal worth up to $1.1bn with MorphoSys
It may have an advantage over these drugs however, as CAR-T therapies are personalised medicines which have complex manufacturing processes.
-
Personalised medicine can improve treatment, but access still an issue
Barriers to access could harm uptake of potentially transformative therapies. Personalised medicines such as gene therapies may improve identification of optimal treatment but gaining access to these treatments still poses an ... For example, NHS England
-
Greater Manchester backs move to outcome-based payment
able to access new and innovative medicines as early as possible and delivering better value for money.”. ... We’re set to see more personalised medicines being launched over the next few years, so additional data will help ensure those treatments
-
CAR-Ts go head-to-head after NICE clears Kymriah in DLBCL
Meindert Boysen, director of the Centre for Health Technology Evaluation at NICE said: “Recommending another revolutionary CAR T-cell therapy for adults with lymphoma represents a step forward for personalised medicine. ... Providing the latest cutting
Immuno-oncology, personalised medicine continues to drive pharma sector
Incyte signs lymphoma deal worth up to $1.1bn with MorphoSys
Greater Manchester backs move to outcome-based payment
CAR-Ts go head-to-head after NICE clears Kymriah in DLBCL
More from news
Approximately 13 fully matching, plus 58 partially matching documents found.
Latest Intelligence
-
How early-stage clinical research is facilitating the new wave of personalised medicines
There are a number of adaptations that CROs and the wider healthcare industry must make to deliver on the promise of personalised medicines. ... For example, it has engaged extensively to understand the priorities of patients in the development and
-
From if to how: when imagination and regulation work together
This is an equation in which continued investment in research, development of novel medicines and increasingly personalised solutions are balanced against maintaining sustainability of healthcare systems during a global economic downturn.
-
The dawn of a new era in medical education
By Annlouise Pendse. We are living in a pivotal moment in medical history. The first wave of personalised medicines is now available and is changing the way diseases are identified and ... delivering often complex personalised medicine.
-
The first, my last, my everything
This growing empowerment arguably has its biggest impact in the arena of high-value medicines. ... We need a better understanding of patients. We’re heading rapidly towards personalised medicines, yet we’re still not personalising the value that we
-
Genomics integration: can the NHS rise to the challenge?
We can then make sure personalised medicine treatment is targeted to the individual so they get the best treatment at the right point in time. ... Last year, NHS England announced that it will focus on earlier diagnosis and more personalised medicines
How early-stage clinical research is facilitating the new wave of personalised medicines
From if to how: when imagination and regulation work together
The dawn of a new era in medical education
The first, my last, my everything
Genomics integration: can the NHS rise to the challenge?
More from intelligence
Approximately 4 fully matching, plus 19 partially matching documents found.
Latest appointments
-
Eduardo Bravo becomes head of EBE
Coming from the field of advanced therapies, he helps bridge the gap between the lab and personalised medicines within a thriving and innovative ecosystem.”.
-
Horizon Discovery appoints executive director
1996. Horizon is a UK-based biotech focused on genomics research and the development of personalised medicines.
Eduardo Bravo becomes head of EBE
Horizon Discovery appoints executive director
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
In the precision medicine era, the line between products and services is blurred
Precision and personalised medicines are more than products, they are services in their own right. ... Personalised and precision medicines are naturally patient-centred (compared to traditional pharmaceuticals), as the individual patient is central to
-
Five key trends in precision and personalised healthcare
Personalised and precision medicines represent an evolution in healthcare, in which traditional clinical information and new data points including genetic data, and healthcare technology come together to match the right patient ... Innovative pricing
-
'Fake news': battling misinformation in healthcare
As the pharmaceutical landscape becomes more complex and as personalised and precision medicines emerge, these stories are increasingly impacting patients and healthcare professionals.
-
Mastering the precision medicine opportunity
Personalised: Developing and choosing medicines that will change the patient experience, from one of hope to one of certainty of response. ... In personalised medicine, we ask if we can use a particular treatment in a patient.
-
Medopad: the up and coming unicorn transforming remote patient monitoring
The company has developed a platform for creating modular apps which can be personalised across numerous patient cohorts, using a combination of artificial intelligence, rich data analysis and a strong understanding ... Healthcare is becoming more precise
More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
-
Senior Account Manager
-
Competitive salary offered
-
Omnichannel Strategy Consultant
-
Competitive Salary
- Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Data shows patients treated with Biogen's MS therapies mount an effective antibody response to COVID-19 vaccination
- US demand for COVID-19 antibody treatments rising fast
- Assessing the value of interim analyses in clinical trials
- AstraZeneca chooses Ireland for $360m manufacturing site
- Gilead’s Trodelvy set for EU approval in breast cancer
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Breaking the silence: It’s time to talk about the menopause
- FDA accepts Regeneron’s REGEN-COV for priority review for treatment of COVID-19
- New data shows Roche's Enspryng significantly reduces neuromyelitis optica spectrum disorder relapses
- Beyond yoga and smoothies – providing real support for employee well-being
- Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death
- Novo Nordisk settles US insulin pricing dispute for $100m
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Onyx Health appoints Dean Forbes
- Sandoz completes acquisition of GSK’s cephalosporin business
- Public is more comfortable with health data sharing if they know it is to support breakthrough treatments and vaccines
PMHub
Apex.co.uk Events and Exhibition Stands
Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...
Latest intelligence
- Breaking the silence: It’s time to talk about the menopause
- Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
- Committing time to making meaningful connections - top 5 tips
- Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
- News:
- Senior Analytics Specialist joins Research Partnership...
